Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Implexion Pharma - Preparation for clinical development of new pharmaceutical strategies for fibrosis diseases

Reference number
Coordinator Implexion Pharma AB
Funding from Vinnova SEK 317 000
Project duration November 2022 - December 2023
Status Completed
Venture Innovative Startups
Call Innovative Impact Startups autumn 2022

Important results from the project

The purpose of this project has been to carry out preparatory steps that facilitate Implexion´s path to clinical studies, with objective of increasing the company´s patient understanding, developing a clinical plan, strengthening the organization and preparing for capitalization. The company has made progress in all areas and is now much better equipped to take on the next step towards clinical studies.

Expected long term effects

** Denna text är maskinöversatt ** The results from the project means, just as expected, that Implexion is now ready for the next stage of development in the company´s progress towards clinical studies. The company now has a better understanding of the patient perspective, the design of remaining studies and requested results from investors and is ready with an organization that is even better suited to take the company forward.

Approach and implementation

** Denna text är maskinöversatt ** The design and implementation of the project has worked well, but it has taken somewhat longer than what was expected when the application was submitted.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 16 February 2024

Reference number 2022-02166